However, INT-777, a specific TGR5 agonist, which was injected into the lateral ventricle of the brain, ameliorated STZ-induced cognitive deficits, suggesting that TGR5 might be a novel and potential target for AD. Here, GPBAR1 is linked to Cognitive impairment.